formaldehyde has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 9 studies
paraform: polymerized formaldehyde; RN given refers to parent cpd; used in root canal therapy
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 5 (55.56) | 2.80 |
| Authors | Studies |
|---|---|
| García-Adrián, S | 1 |
| Trilla-Fuertes, L | 1 |
| Gámez-Pozo, A | 1 |
| Chiva, C | 1 |
| López-Vacas, R | 1 |
| López-Camacho, E | 1 |
| Zapater-Moros, A | 1 |
| Lumbreras-Herrera, MI | 1 |
| Hardisson, D | 1 |
| Yébenes, L | 1 |
| Zamora, P | 1 |
| Sabidó, E | 1 |
| Fresno Vara, JÁ | 1 |
| Espinosa, E | 1 |
| Steiner, C | 1 |
| Lescuyer, P | 1 |
| Cutler, P | 1 |
| Tille, JC | 1 |
| Ducret, A | 1 |
| Salman, G | 1 |
| Aldujaily, E | 1 |
| Jabardi, M | 1 |
| Qassid, OL | 1 |
| Makrantonakis, AE | 1 |
| Zografos, E | 1 |
| Gazouli, M | 1 |
| Dimitrakakis, K | 1 |
| Toutouzas, KG | 1 |
| Zografos, CG | 1 |
| Kalapanida, D | 1 |
| Tsiakou, A | 1 |
| Samelis, G | 1 |
| Zagouri, F | 1 |
| Panchal, NK | 1 |
| Bhale, A | 1 |
| Chowdary, R | 1 |
| Verma, VK | 1 |
| Beevi, SS | 1 |
| Jovanović, B | 1 |
| Sheng, Q | 1 |
| Seitz, RS | 1 |
| Lawrence, KD | 1 |
| Morris, SW | 1 |
| Thomas, LR | 1 |
| Hout, DR | 1 |
| Schweitzer, BL | 1 |
| Guo, Y | 1 |
| Pietenpol, JA | 1 |
| Lehmann, BD | 1 |
| Vaca-Paniagua, F | 1 |
| Alvarez-Gomez, RM | 1 |
| Maldonado-Martínez, HA | 1 |
| Pérez-Plasencia, C | 1 |
| Fragoso-Ontiveros, V | 1 |
| Lasa-Gonsebatt, F | 1 |
| Herrera, LA | 1 |
| Cantú, D | 1 |
| Bargallo-Rocha, E | 1 |
| Mohar, A | 1 |
| Durand, G | 1 |
| Forey, N | 1 |
| Voegele, C | 1 |
| Vallée, M | 1 |
| Le Calvez-Kelm, F | 1 |
| McKay, J | 1 |
| Ardin, M | 1 |
| Villar, S | 1 |
| Zavadil, J | 1 |
| Olivier, M | 1 |
| Wong, EM | 1 |
| Joo, JE | 1 |
| McLean, CA | 1 |
| Baglietto, L | 1 |
| English, DR | 1 |
| Severi, G | 1 |
| Hopper, JL | 1 |
| Milne, RL | 1 |
| FitzGerald, LM | 1 |
| Giles, GG | 1 |
| Southey, MC | 1 |
| Korlimarla, A | 1 |
| Prabhu, JS | 1 |
| Remacle, J | 1 |
| Rajarajan, S | 1 |
| Raja, U | 1 |
| C E, A | 1 |
| Srinath, BS | 1 |
| Manjunath, S | 1 |
| K S, G | 1 |
| Correa, M | 1 |
| M S N, P | 1 |
| Sridhar, TS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel With or Without RAD001 in Patients With Triple-negative Locally Advanced Breast Cancer.[NCT00930930] | Phase 2 | 145 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Defined as patients that did not undergo complete removal of a cancerous breast (mastectomy). (NCT00930930)
Timeframe: at the time of surgery, week 15-18
| Intervention | participants (Number) |
|---|---|
| Cisplatin and Paclitaxel + RAD001 | 38 |
| Cisplatin and Paclitaxel + Placebo | 19 |
Pathological complete response is defined as no residual tumor on histopathological analysis of both breast and axillary contents. (NCT00930930)
Timeframe: at time of surgery, week 15-18
| Intervention | participants (Number) |
|---|---|
| Cisplatin and Paclitaxel + RAD001 | 34 |
| Cisplatin and Paclitaxel + Placebo | 17 |
Per RECIST criteria v. 1.0: measurable lesions: complete response (CR) disappearance of target lesions, partial response (PR) > 30% decrease in the sum of the longest diameter (LD) of target lesions, progressive disease (PD) > 20% increase in the sum of the LD of target lesions or appearance of new lesions, stable disease (SD) neither sufficient decrease nor increase of the sum of smallest sum of the LD of target lesions (NCT00930930)
Timeframe: After treatment, week 12-15
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response | Partial Response | Stable Disease | Progressive Disease | Not Evaluable | |
| Cisplatin and Paclitaxel + Placebo | 23 | 19 | 5 | 0 | 1 |
| Cisplatin and Paclitaxel + RAD001 | 48 | 27 | 18 | 2 | 1 |
Tables represent the number of patients with their worst-grade toxicity at each of five grades (grade 1, least severe to grade 5, most severe) following NCI Common Toxicity Criteria. Not all participants necessarily have an adverse event, thus not everyone will be accounted for in worst-grade toxicities. Likewise, one participant can potentially have more than one event in various grades 1-5 which accounts for the difference in number of patients analyzed and total number in the worst-grade toxicity tables. (NCT00930930)
Timeframe: week 12
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Number of patients with worst-grade toxicity 1 | Number of patients with worst-grade toxicity 2 | Number of patients with worst-grade toxicity 3 | Number of patients with worst-grade toxicity 4 | Number of patients with worst-grade toxicity 5 | |
| Cisplatin and Paclitaxel + Placebo | 5 | 28 | 9 | 1 | 0 |
| Cisplatin and Paclitaxel + RAD001 | 9 | 40 | 39 | 3 | 0 |
9 other studies available for formaldehyde and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Molecular characterization of triple negative breast cancer formaldehyde-fixed paraffin-embedded samples by data-independent acquisition proteomics.
Topics: Female; Formaldehyde; Humans; Paraffin Embedding; Proteome; Proteomics; Triple Negative Breast Neopl | 2022 |
Relative Quantification of Proteins in Formalin-Fixed Paraffin-Embedded Breast Cancer Tissue Using Multiplexed Mass Spectrometry Assays.
Topics: Biomarkers; Formaldehyde; Humans; Mass Spectrometry; Paraffin Embedding; Peptides; Proteins; Tissue | 2022 |
Investigating the clinical significance of EGFR expression using machine learning in a series of Iraqi patients with triple-negative breast cancer.
Topics: ErbB Receptors; Estrogens; Formaldehyde; Humans; Immunohistochemistry; Iraq; Machine Learning; Proge | 2022 |
PD-L1 Gene Polymorphisms rs822336 G>C and rs822337 T>A: Promising Prognostic Markers in Triple Negative Breast Cancer Patients
Topics: B7-H1 Antigen; Biomarkers, Tumor; Female; Formaldehyde; Humans; Neoplasm Recurrence, Local; Polymorp | 2022 |
PCR Amplifiable DNA from Breast Disease FFPE Section for Mutational Analysis.
Topics: Breast Diseases; DNA; DNA Fragmentation; DNA Mutational Analysis; Exons; Formaldehyde; Humans; Paraf | 2020 |
Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue.
Topics: Female; Formaldehyde; Gene Expression Regulation, Neoplastic; High-Throughput Nucleotide Sequencing; | 2017 |
Revealing the Molecular Portrait of Triple Negative Breast Tumors in an Understudied Population through Omics Analysis of Formalin-Fixed and Paraffin-Embedded Tissues.
Topics: Adult; Female; Formaldehyde; Humans; In Vitro Techniques; Middle Aged; Paraffin; Retrospective Studi | 2015 |
Tools for translational epigenetic studies involving formalin-fixed paraffin-embedded human tissue: applying the Infinium HumanMethyation450 Beadchip assay to large population-based studies.
Topics: Adult; Aged; BRCA1 Protein; Cohort Studies; DNA Methylation; DNA, Neoplasm; Epigenesis, Genetic; Fem | 2015 |
Identification of BRCA1 Deficiency Using Multi-Analyte Estimation of BRCA1 and Its Repressors in FFPE Tumor Samples from Patients with Triple Negative Breast Cancer.
Topics: BRCA1 Protein; Carboplatin; Female; Formaldehyde; Gene Expression Regulation, Neoplastic; Humans; In | 2016 |